Using the currently available proteome databases and based on the concept that a rare sequence is a potential epitope, epitopic sequences derived from Mycobacterium tuberculosis were examined for similarity score to the proteins of the host in which the epitopes were defined. We found that: (i) most of the bacterial linear determinants had peptide fragment(s) that were rarely found in the host proteins and (ii) the relationship between low similarity and epitope definition appears potentially applicable to T-cell determinants. The data confirmed the hypothesis that low-sequence similarity shapes or determines the epitope definition at the molecular level and provides a potential tool for designing new approaches to prevent, diagnose, and treat tuberculosis and other infectious diseases.
1. Introduction
Mycobacterium tuberculosis is the causative agent of tuberculosis (TB) and is a major infectious pathogen. A resurgence of tuberculosis has marked the beginning of the third millennium, with about 8 million new cases and 1.8 million deaths annually worldwide attributed to M. tuberculosis [1]. More recently, the World Health Organization’s Global Tuberculosis Control Report 2009 estimated 9.27 million cases of TB in 2007 [2], an increase from 9.24 million cases in 2006, 8.3 million cases in 2000, and 6.6 million cases in 1990. These numbers underscore the need to develop and characterize rational and effective TB therapies and diagnostic reagents. Currently, the M. bovis bacillus Calmette-Guérin (BCG) vaccine is used against TB. BCG has excellent immuno-potentiating properties, but it is not uniformly effective [3], and efforts to develop a more effective M. bovis-derived vaccine against TB have not had satisfactory results [4, 5]. Moreover, the emergence of multiple-drug-resistant TB [6] and the increasing prevalence of mycobacterial disease in people with acquired immunodeficiency syndrome [7] add urgency to the need for an effective vaccine against TB.
Recent studies have provided convincing evidence that antibodies can protect against mycobacterial infections [8]. Passive immunization using mono- and polyclonal antibodies and humoral immune responses against specific mycobacterial antigens in experimental animals have shown that antibodies may play an anti-TB role [9–11]. The epitopic characterization of mycobacterial antigens is performed antigen-by-antigen, searching for specific peptide features and epitope-paratope interaction domains for each mycobacterial protein antigen [12–14]. In essence, the common molecular basis and the fundamental rules underlying the immune function of specific peptide units remain unexplained [15, 16]. Little is known about the structure-function relationship(s) of protein sequences in immunology. This lack of knowledge may underlie the confusion surrounding neutralizing versus nonneutralizing antibodies, harmful vaccine side effects, and imprecise diagnostic tools.
Within this framework, we propose that rare peptide sequences, that is, peptide motifs rarely found in host proteins, elicit an immune response. Unique protein sequences are more likely to evoke an immune response than are highly repeated motifs, which would be immunogenically silenced by tolerance. We have previously validated the relationship between sequence rarity and peptide immunoreactivity in cancer, autoimmunity, and infectious disease models. We reported several examples of specific targeting of peptide regions with no or limited sequence similarity to the host proteome, including mono- and polyclonal antibodies raised against EC Her-2/Neu oncoprotein [17], desmoglein-3 [18], melan-a/MART-1 [19], high-molecular-weight melanoma-associated-antigen [20, 21], tyrosinase [22, 23], prostate-specific-antigen [24], HPV16 E7 [25], HCV [26], and influenza A [27] proteins. In addition, a review of the epitope mapping literature revealed that most peptide epitopes obey the low-similarity rule [28], further supporting our hypothesis. Taken together, our data [17–27] and findings from other research [28] suggest that unique peptide sequences are more likely to be immunogenic than are highly repeated peptide sequences, which may be immuno-tolerated.
In the present study, we investigated the low-similarity hypothesis in M. tuberculosis antigen epitopes with the aim of defining immunogenic peptide sequences that may be effective for anti-TB immunotherapy. We studied validated M. tuberculosis epitopes currently cataloged in the Immune Epitope Database and Analysis Resources (IEDB) (http://www.immuneepitope.org/) [29, 30]. We report that most of the mycobacterial epitopes involved in the immune response are characterized by a low level of similarity to the host proteome.
2. Methods
The IEDB contains hundreds of mycobacterial epitopes derived from various strains and with different characteristics [30]. Specifically, the IEDB contains B- and T-cell mycobacterial epitopes that are (a) linear or conformational; (b) derived from M. tuberculosis, M. bovis, M. Avium, and M. leprae; (c) of different lengths (up to 36 aa) [31]; and (d) have sequences that were negative, positive, or produced mixed negative/positive results in immunoassays. The present report focused on B-cell linear epitopes derived from M. tuberculosis that were positive in immunoassays.
These mycobacterial epitopes were analyzed for similarity to the host proteins with the aim of identifying identical amino acid groupings that were common sequences [32]. The amino acid groupings were linear pentapeptides. Pentapeptides were used because the canonical literature indicates that five to six amino acids are a sufficient minimal determinant for an epitope-paratope interaction, and thus a pentapeptide can act as an immune unit and play a crucial role in cell immunoreactivity and antigen-antibody recognition [33, 34].
Fifty-six M. tuberculosis epitopes cataloged as immuno-positive at IEDB resource were dissected into pentamer motifs offset by one residue: that is, WDEDG, DEDGE, EDGEK, DGEKR, and so forth. Then, each 5-mer was used as a probe to scan the entire host proteome searching for identical matches using the PIR protein database and PIR perfect peptide match program (http://pir.georgetown.edu/pirwww/) [35]. The number of matches of each mycobacterial pentamer to the host proteome indicates the similarity score that can range from no matches to hundreds of matches. Following previous experimental data, a pentapeptide fragment that has about five (or fewer) perfect matches to the host proteome was considered to be a low-similarity sequence, that is, a rare fragment [17–28].
3. Results3.1. Low-Similarity Sequences and B-Cell Epitopes
We examined the linear M. tuberculosis-derived B-cell epitopes cataloged in the IEDB [30], using pentapeptide probes as described above and report the similarity scores (Table 1).
Similarity analysis of M. tuberculosis B-cell epitopes to the host proteome.
Epitope Source Name
IEDB ID1
Epitope Sequence2
Number of Matches3
Host Proteome4
Refs.
10 kDa chaperonin
3293
wdedGEKRIpldvae
4
H
[12, 36]
10 kDa chaperonin
6508
PDTAKekpqegtvva5
3
H
[12, 36]
10 kDa chaperonin
3294
ldvaegdtvIYSKY5
2
H
[12, 36]
10 kDa chaperonin
1011756
gtvvavgpGRWDEdge5
3
H
[37–39]
10 kDa chaperonin
1011758
GRWDEdgekripldva
3
H
[37–39]
10 kDa chaperonin
3290
etttasglviPDTAK5
3
H
[12, 36, 38]
10 kDa chaperonin
3289
dkilvQANEAettta
1
H
[12, 36]
6 kDa ESAT5
8105
yqgvQQKWD5
1
M
[40]
6 kDa ESAT
8086
eQQWNFagieaaa5
0
M
[40]
6 kDa ESAT
8090
DEGKQsltk5
2
M
[40]
6 kDa ESAT
8106
aaAWGGSgsEAYQGvQQKWData5
3, 1, 1
M
[40]
DNAK
1052559
lvyQTEKF
4
H
[41]
DNAK
1052560
vyQTEKFv
4
H
[41]
DNAK
1052558
yQTEKFvk
4
H
[41]
DNAK
1052561
qTEKFVke
3
H
[41]
DNAK
1052562
TEKFVkeq
3
H
[41]
DNAK
1052583
lNKVDAav
4
H
[41]
DNAK
1052584
NKVDAava
4
H
[41]
DNAK
1052589
aeaEGGTW
3
H
[41]
DNAK
1052591
aegGTWRI
2
H
[41]
DNAK
1052593
ggTWRIGY
0
H
[41]
DNAK
1052594
WRIGYfgh
0
H
[41]
DNAK
1052595
riGYFGHq
2
H
[41]
DNAK
1052596
igYFGHQv
1
H
[41]
DNAK
1052597
GYFGHqvg
2
H
[41]
DNAK
1052598
YFGHQvgd
1
H
[41]
DNAK
24658
HQVGDgea
1
H
[41]
DNAK
1052627
lrsSSGCV
5
H
[41]
DNAK
1052628
rssSGCVT
4
H
[41]
DNAK
1052629
sssGCVTG
4
H
[41]
DNAK
1052630
ssgCVTGH
1
H
[41]
DNAK
1052631
cvTGHWRc
0
H
[41]
DNAK
1052632
VTGHWrcp
0
H
[41]
DNAK
1052633
TGHWRCpp
0
H
[41]
DNAK
1052549
HWRCPprr
1
H
[41]
DNAK
1052550
WRCPPrrr
1
H
[41]
ESAT-6-like protein ESXB
6090
laqeagNFERIsgdl5
2
H
[42]
ESAT-6-like protein ESXB
6090
laqeagNFERIsgdl
1
M
[42]
Immunogenic protein MPT64
1043665
nitsATYQSaipprgtqavv
1, 0
H
[43]
Immunogenic protein MPT64
1043668
hptttyKAFDWdqayrkpit
0
H
[43]
Lipoprotein LPQH
1034449
vtgsvvCTTAAgnvniaigg5
2
M
[44]
Lipoprotein LPQH
1107625
vtGSVVC5
5
M
[44]
Lipoprotein LPQH
1107627
VNKSFei
1
M
[44]
Lipoprotein LPQH
1052656
VKRGLtvavagaailvagls
2
M
[45]
Lipoprotein LPQH
1034455
taspgaasgpkvvidGKDQN
4
M
[44]
Lipoprotein LPQH
1018364
dMANPMspvnksfeievtcs
0
M
[44]
MTP40 protein
1013654
gprlyGEMTMqgtrkprpsgp
2
H
[46]
MTP40 protein
1011740
ttlGMHCGsfgsapsng
0
H
[46]
MTP40 protein
1011751
mlgtGTPNRarINFNC
3, 3
H
[46]
MTP40 protein
1011736
MLGNApsvvpnTTLGM
4, 3
H
[46]
MTP40 protein
1011754
INFNCevWSNVSetisgprly
3, 2
H
[46]
Phosphate-binding protein 1
1127065
lfnlWGPAFherypnvtita
1
M
[44]
Phosphate-binding protein 1
1019382
kqdpegWGKSPgfgttvdfp
1
M
[47]
Phosphate-binding protein 1
1107628
GPAFHer
1
M
[44]
Phosphate-binding protein 1
1123943
gnggMVTGCaetpgcvayig
1
M
[48]
Phosphate-binding protein 1
1107630
gfasKTPANqais
1
M
[44]
1IEDB ID Reference Dataset of Mycobacterial Immune Epitopes: http://iedb.zendesk.com/entries/18171-reference-datasets-of-mycobacterial-immune-epitopes.
2Epitope sequence with amino acid sequence in one-letter code. Low-similarity pentapeptides in capital letters.
3Number of times the low-similarity pentapeptide fragment(s) occur(s) in the set of proteins that comprehensively form the host proteome (see under Methods and [17–27]).
4Host proteome: H, human; M, murine.
5Sequences entirely or partially contained in M. tuberculosis T-cell epitopes [36, 49–52].
6ESAT, early secretory antigenic target.
As shown in Table 1, most of the mycobacterial B-cell epitopes contain pentapeptides that are rare or absent in the host proteins. Furthermore, preliminary screening revealed that a few B-cell epitopes were also T-cell epitopes (Table 1, footnote 5) [36, 49–52].
The relationship between low-similarity sequences and mycobacterial epitopes was further confirmed by extending the similarity analysis to the COOH domain of the mycobacterial DNAK protein. The DNAK chaperon protein is a member of the highly conserved heat shock protein family and is a protein antigen involved in the immune response to mycobacteria [53, 54]. In particular, the DNAK carboxy-terminus domain is highly immunogenic [41, 55] and hosts several of the epitopes described in the IEDB database (Table 1) [41]. Thus, the COOH domain of the mycobacterial DNAK protein was suitable for verifying the similarity-immunogenicity link. In brief, the primary sequence of the DNAK COOH-terminus domain (aa 500–609) was dissected into pentamers that were probed against the human proteome by the computer-assisted similarity analysis described in the Methods section. Then, the epitopic sequences were allocated along the mycobacterial-versus-human similarity profile.
Figure 1 shows the similarity profile of the DNAK COOH-terminus protein to the human proteome and the localization of the linear epitopes along the antigenic sequence. It can be seen that the carboxy terminal sequence of the mycobacterial chaperon protein has pentapeptides occurring frequently in the human proteome as well as unique fragments. Five pentamers (i.e., TWRIGY, WRIGY, VTGHW, TGHWR, and GHWRC) were unique to the DNAK COOH-terminus domain and these accounted for 5% of the total DNAK pentamers. The remaining 100 pentapeptides were repeated at different extent throughout the human proteome and occurred a total of 2468 times. Furthermore, and most importantly, Figure 1 shows that the peptide epitopes recognized by the human sera, as demonstrated by Elsaghier et al. [41], were among the mycobacterial peptide fragments that had a low similarity to the human proteome. That is, the unique pentapeptide signatures of the DNAK carboxy-terminus domain coincided with the epitopic motifs involved in immune recognition, indicating a direct relationship between low similarity and the humoural antibody response. Conversely, M. tuberculosis peptides not responsive to the human sera had a high number of pentamer matches to the human proteome (Figure 1, black arrows numbered from 6 to 15).
Similarity profile of the mycobacterial DNAK carboxy-terminus domain versus the human proteome at the pentapeptide level. The columns indicate the number of DNAK pentapeptide occurrences in the human proteome. DNAK corresponds to hsp70 protein, UniProt accession: P0A5B9; length: 609 aa. The numbered arrows indicate the location of mycobacterial peptide sequences immunoassayed with human sera [41]. Black arrows refer to the immuno-negative peptide sequences corresponding to IEDB ID: (6) 1212577 (aa FVKEQREA); (7) 1212579 (aa VKEQREAE); (8) 1212581 (aa KEQREAEG); (9) 1212582 (aa EQREAEGG); (10) 1212585 (aa QREAEGGS); (11) 1212586 (aa REAEGGSK); (12) 1212589 (aa EAEGGSKV); (13) 1212590 (aa AEGGSKVP); (14) 1212593 (aa EGGSKVPE); (15) 1212595 (aa GGSKVPED). Red arrows refer to the positive epitopic sequences corresponding to IEDB ID: (1) 1052559; (2) 1052560; (3) 1052558; (4) 1052561; (5) 1052562; (16) 1052583; (17) 1052584; (18) 1052589; (19) 1052591; (20) 1052593; (21) 1052594; (22) 1052595; (23) 1052596; (24) 1052597; (25) 1052598; (26) 24658; (27) 1052627; (28) 1052628; (29) 1052629; (30) 1052630; (31) 1052631; (32) 1052632; (33) 1052633; (34) 1052549; (35) 1052550. See Table 1 for amino acid sequence details. IEDB ID Reference Dataset of Mycobacterial Immune Epitopes: http://iedb.zendesk.com/entries/18171-reference-
datasets-of-mycobacterial-immune-epitopes.
3.2. Low-Similarity Sequences and T-Cell Epitopes
The low-similarity M. tuberculosis B-cell epitopes hosted T-cell epitopes [36, 49–52] in several cases (Table 1). These data suggest that low-similarity influences the T- as well as the B-cell immune response, a finding that might be used in defining T-cell epitopes. Characterization of T-cell epitopes is complicated by different sets of rules governing the immune response. The problems include, but are not limited to, epitope hierarchy, immunoprevalence and immunodominance [56], variable epitopic length, the epitope major histocompatibility complex (MHC) binding potential and the difficulty of correctly predicting MHC binding activities in the majority of the test-set peptides [57], and the degenerate T-cell receptor recognition [22].
In this intricate context, the low-similarity hypothesis may provide insight for the structural characterization of immunogenic T-cell epitopic sequences. We know that the optimal peptide length for MHC binding is between nine and fifteen amino acids, and the central 5-6 residues contribute the majority of the specific contacts [59]. Thus, as previously proposed [19], the structural features that define an immunogenic T-cell epitope may be characterized by the MHC binding terminal residues flanking a central low-similarity core formed by 5-6 residues. This model is illustrated in Figure 2 using an immunodominant mycobacterial T-cell epitope validated and described by Ivanyi et al. [58]. The immunodominant p61–80/PT19 mycobacterial epitope (VTGSVVCTTAAGNVNIAIGG) has a critical core formed by five residues (AGNVN, aa 71–75): a single amino acid substitution with N73A impairs T-cell immunogenicity of the target p61–80/PT19 epitope. Our similarity analysis reveals that this substitution causes a shift in the proteomic similarity level of the five core residues (aa 71–75) that changes from one match (aa sequence AGNVN) to eight matches (aa sequence AGAVN) and “hides” the 5-mer core from the immune system.
The immunogenic impact of a single amino acid substitution in the five core residues (AGNVN, aa 71–75) of the immunodominant p61–80/PT19 mycobacterial epitope (VTGSVVCTTAAGNVNIAIGG). The substitution of N73A impairs T immunogenicity for the target epitope and changes the proteomic similarity level of the five core residues (aa 71–75 underlined) from one match (aa sequence AGNVN) to eight matches (aa sequence AGAVN). (a) The immunogenic MHC-peptide complex containing the central low-similarity pentapeptide AGNVN (in white); (b) The nonimmunogenic MHC-peptide complex containing the higher similarity pentapeptide AGAVN (in gray). Immunoreactivity and mutagenesis experiments are described in [58]. The figures are modified versions of the original drawings from the website http://www.iayork.com/ by kind authorization of Professor Ian York, University of Michigan.
The model illustrated in Figure 2 is supported by reports that the HFMPT pentapeptide is a minimal antigenic determinant for MHC class I-restricted T lymphocytes [60], and the KYVKQ pentapeptide is a minimal antigenic determinant for CD4(+) T-cell clones [61]. Moreover, the proteomic similarity values for HFMPT and KYVKQ were no matches and one match, respectively.
4. Discussion
In this study, we explored the IEDB resources to define and characterize immunogenic mycobacterial epitopes that could be used for effective anti-TB immunotherapy. We observed that the immunological information carried by the M. tuberculosis antigens was localized in rare peptide fragments, confirming the relationship between low-similarity and immunogenicity. Sequences containing pentapeptide fragment(s) with low similarity to the host proteome appear to be those involved in the humoral antibody recognition of the mycobacterial antigen and may also influence T-cell immunoreactivity too.
Our findings provide a method for investigating the immune potential of the mycobacterial proteome, and thus, may help elucidate M. tuberculosis immunobiology, one of the primary challenges in current tuberculosis research. This is an important issue, particularly because the epitopic characterization of mycobacterial antigens advances slowly, antigen-by-antigen [12–14].
Moreover, mycobacterial antigenic motifs rarely found in host proteins are more likely to serve as potential immunogenic antigens. Use of short peptide modules rather than full-length mycobacterial antigens in vaccines may increase specificity and efficacy. It has been understood since the 1980s that chemically synthesized small peptides can induce antibodies that react with intact proteins [62]. Furthermore, peptide-based vaccines have been successfully used against several pathologies and infectious diseases. For example, tumour antigen-derived peptides evoked potent antitumour immunity in the murine melanoma M-3 [63]; cytotoxic CD4+ and CD8+ T lymphocytes generated by mutant p21-ras (12Val) peptide vaccination selectively killed autologous tumour cells carrying this mutation [64]; Her-2/neu peptide (aa 657–665) is an immunogenic epitope of Her-2/neu oncoprotein with potent antitumour properties [65]; synthetic peptides identified as antigenic sites on the S1 subunit of pertussis toxin induced especially high antibody titres against native pertussis toxin in mice [66]; a linear peptide containing minimal T- and B-cell epitopes of Plasmodium falciparum circumsporozoite protein provided protection against a transgenic sporozoite challenge [67]. These findings indicate that the use of exact immunogenic mycobacterial peptide sequences may provide the most effective active and passive immunotherapeutic anti-TB approaches. In addition, a major obstacle to antibody-based anti-TB therapy is the risk of adverse effects that range from Lupus vulgaris to granulomatous hepatitis [68–72], possibly caused by cross-reactivity [73]. The use of low-similarity peptides may allow the development of effective vaccines without adverse side-effects [74]. In conclusion, the findings of the present study may provide guidance in the analysis, identification, and utilization of the B- and T-cell response in vaccination against mycobacterial and other infectious diseases.
Acknowledgments
This study was made possible by the free access to the Immune Epitope Database at the National Health Institutes, Bethesda, MD. We thank Professor Ian York, University of Michigan, for allowing us to use his figures. We are indebted to the Referees for precious comments and suggestions. Of course, we remain responsible for any remaining errors.
CorbettE. L.WattC. J.WalkerN.The growing burden of tuberculosis: global trends and interactions with the HIV epidemic200316391009102110.1001/archinte.163.9.10092-s2.0-0012746992The World Health Organization Report2009Geneva, SwitzerlandWHOFineP. E. M.BCG: the challenge continues200133424324510.1080/0036554013000771442-s2.0-0035061214HuygenK.DNA vaccines against mycobacterial diseases2006163732-s2.0-3454838384910.2217/17460913.1.1.63TangheA.DangyJ.-P.PluschkeG.HuygenK.khuygen@pasteur.beImproved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boosting200823, article e1992-s2.0-003105975410.1371/journal.pntd.0000199MeyaD. B.McAdamK. P.The TB pandemic: an old problem seeking new solutions2007261430932910.1111/j.1365-2796.2007.01795.x2-s2.0-33947511253NissapatornV.KuppusamyI.JosephineF. P.JamaiahI.RohelaM.Khairul AnuarA.Tuberculosis: a resurgent disease in immunosuppressed patients200637supplement 3153160AbebeF.BjuneG.The protective role of antibody responses during Mycobacterium tuberculosis infection2009157223524310.1111/j.1365-2249.2009.03967.x2-s2.0-67650671886XuY.ZhuB.WangQ.Recombinant BCG coexpressing Ag85B, ESAT-6 and mouse-IFN-γ confers effective protection against Mycobacterium tuberculosis in C57BL/6 mice200751348048710.1111/j.1574-695X.2007.00322.x2-s2.0-35948944602QieY. Q.WangJ. L.ZhuB. D.Evaluation of a new recombinant BCG which contains mycobacterial antigen ag85B-mpt64190-198-mtb8.4 in C57/BL6 mice200867213313910.1111/j.1365-3083.2007.02048.x2-s2.0-38149068140Chang-HongS.Xiao-WuW.HaiZ.Ting-FenZ.Li-MeiW.Zhi-KaiX.Immune responses and protective efficacy of the gene vaccine expressing Ag85B and ESAT6 fusion protein from Mycobacterium tuberculosis200827419920710.1089/dna.2007.06482-s2.0-42149175510HussainR.DockrellH. M.ChiangT. J.Dominant recognition of a cross-reactive B-cell epitope in Mycobacterium leprae 10 K antigen by immunoglobulin G1 antibodies across the disease spectrum in leprosy199996462062710.1046/j.1365-2567.1999.00740.x2-s2.0-0032927398SinghK. K.SharmaN.VargasD.Peptides of a novel Mycobacterium tuberculosis-specific cell wall protein for immunodiagnosis of tuberculosis2009200457158110.1086/6035392-s2.0-69149103385BaassiL.SadkiK.SeghrouchniF.Evaluation of a multi-antigen test based on B-cell epitope peptides for the serodiagnosis of pulmonary tuberculosis20091378488542-s2.0-67651236108GowthamanU.AgrewalaJ. N.In silico tools for predicting peptides binding to HLA-class II molecules: more confusion than conclusion20087115416310.1021/pr070527b2-s2.0-38649118833BlytheM. J.FlowerD. R.Benchmarking B cell epitope prediction: underperformance of existing methods200514124624810.1110/ps.0410595052-s2.0-11144246404MittelmanA.LuccheseA.SinhaA. A.KanducD.Monoclonal and polyclonal humoral immune response to EC HER-2/neu peptides with low similarity to the host's proteome200298574174710.1002/ijc.102592-s2.0-0037051685LuccheseA.alucchese@hotmail.comMittelmanA.LinM.-S.KanducD.d.kanduc@biologia.uniba.itSinhaA. A.ans2003@med.cornell.eduEpitope definition by proteomic similarity analysis: identification of the linear determinant of the anti-Dsg3 MAb 5H1020042, article 432-s2.0-494424040910.1186/1479-5876-2-43TiwariR.GeliebterJ.LuccheseA.MittelmanA.KanducD.Computational peptide dissection of Melan-a/MART-1 oncoprotein antigenicity200425111865187110.1016/j.peptides.2004.07.0042-s2.0-6344222970MittelmanA.TiwariR.LuccheseG.WillersJ.DummerR.KanducD.Identification of monoclonal anti-HMW-MAA antibody linear peptide epitope by proteomic database mining2004123467067510.1111/j.0022-202X.2004.23417.x2-s2.0-4644309011DummerR.MittelmanA.FanizziF. P.LuccheseG.WillersJ.KanducD.Non-self-discrimination as a driving concept in the identification of an immunodominant HMW-MAA epitopic peptide sequence by autoantibodies from melanoma cancer patients2004111572072610.1002/ijc.203102-s2.0-4043057315LuccheseA.WillersJ.MittelmanA.KanducD.DummerR.Proteomic scan for tyrosinase peptide antigenic pattern in vitiligo and melanoma: role of sequence similarity and HLA-DR1 affinity200517510700970202-s2.0-27744523641WillersJ.LuccheseA.MittelmanA.DummerR.KanducD.Definition of anti-tyrosinase MAb T311 linear determinant by proteome-based similarity analysis200514754355010.1111/j.0906-6705.2005.00327.x2-s2.0-21244498559StufanoA.KanducD.Proteome-based epitopic peptide scanning along PSA2009861364010.1016/j.yexmp.2008.11.0092-s2.0-59249102885KanducD.LuccheseA.MittelmanA.Individuation of monoclonal anti-HPV16 E7 antibody linear peptide epitope by computational biology20012212198119852-s2.0-0035752701KanducD.TessitoreL.LuccheseG.KusalikA.FarberE.MarincolaF. M.Sequence uniqueness and sequence variability as modulating factors of human anti-HCV humoral immune response20085781215122310.1007/s00262-008-0456-y2-s2.0-44249084228LuccheseG.StufanoA.KanducD.Proteome-guided search for influenza A B-cell epitopes2009571889210.1111/j.1574-695X.2009.00582.x2-s2.0-69949150577KanducD.d.kanduc@biologia.uniba.it“Self-nonself” peptides in the design of vaccines20091528328332892-s2.0-003421081110.2174/138161209789105135PetersB.SidneyJ.BourneP.The immune epitope database and analysis resource: from vision to blueprint200533, article e91BlytheM. J.mblythe@liai.orgZhangQ.qlehmann@liai.orgVaughanK.An analysis of the epitope knowledge related to Mycobacteria200731, article 102-s2.0-1344430147210.1186/1745-7580-3-10ChakhaiyarP.NagalakshmiY.ArunaB.MurthyK. J. R.KatochV. M.HasnainS. E.Regions of high antigenicity within the hypothetical PPE major polymorphic tandem repeat open-reading frame, Rv2608, show a differential humoral response and a low T cell response in various categories of patients with tuberculosis200419071237124410.1086/4239382-s2.0-4644269598MayA. C. W.Percent sequence identity: the need to be explicit200412573773810.1016/j.str.2004.04.0012-s2.0-2342564913OldstoneM. B. A.Molecular mimicry and immune-mediated diseases19981213125512652-s2.0-0031664697LuccheseG.StufanoA.TrostB.KusalikA.KanducD.Peptidology: short amino acid modules in cell biology and immunology200733470370710.1007/s00726-006-0458-z2-s2.0-36448961979WuC. W.YehL.-S.HuangH.The protein information resource200331134534710.1093/nar/gkg0402-s2.0-0037246063HussainR.ShahidF.ZafarS.DojkiM.DockrellH. M.Immune profiling of leprosy and tuberculosis patients to 15-mer peptides of Mycobacterium leprae and M. tuberculosis GroES in a BCG vaccinated area: implications for development of vaccine and diagnostic reagents2004111446247110.1111/j.0019-2805.2004.01839.x2-s2.0-1842734401Chua-IntraB.PeerapakornS.DaveyN.T-cell recognition of mycobacterial GroES peptides in Thai leprosy patients and contacts19986610490349092-s2.0-0031685594Chua-IntraB.IvanyiJ.HillsA.TholeJ.MorenoC.VordermeierH. M.Predominant recognition of species-specific determinants of the GroES homologues from Mycobacterium leprae and M. tuberculosis1998931647210.1046/j.1365-2567.1998.00400.x2-s2.0-0031952425Chua-IntraB.WilkinsonR. J.IvanyiJ.Selective T-cell recognition of the N-terminal peptide of GroES in tuberculosis20027031645164710.1128/IAI.70.3.1645-1647.20022-s2.0-0036176298HarboeM.MalinA. S.DockrellH. S.B-cell epitopes and quantification of the ESAT-6 protein of Mycobacterium tuberculosis19986627177232-s2.0-0031931453ElsaghierA.LathigraR.IvanyiJ.Localisation of linear epitopes at the carboxy-terminal end of the mycobacterial 71 kDa heat shock protein19922991153115610.1016/0161-5890(92)90049-42-s2.0-0026711182SpencerJ. S.KimH. J.MarquesA. M.Comparative analysis of B- and T-cell epitopes of Mycobacterium leprae and Mycobacterium tuberculosis culture filtrate protein 1020047263161317010.1128/IAI.72.6.3161-3170.20042-s2.0-2542626802RocheP. W.FengC. G.BrittonW. J.Human T-cell epitopes on the Mycobacterium tuberculosis secreted protein MPT6419964366626702-s2.0-0029934335HarrisD. P.VordermeierH.-M.AryaA.BogdanK.MorenoC.IvanyiJ.Immunogenicity of peptides for B cells is not impaired by overlapping T-cell epitope topology19968833483542-s2.0-0029895575AshbridgeK. R.BäckströmB. T.LiuH.-X.Mapping of T helper cell epitopes by using peptides spanning the 19-kDa protein of Mycobacterium tuberculosis: evidence for unique and shared epitopes in the stimulation of antibody and delayed-type hypersensitivity responses19921487224822552-s2.0-0026510074FallaJ. C.ParraC. A.MendozaM.Identification of B- and T-cell epitopes within the MTP40 protein of Mycobacterium tuberculosis and their correlation with the disease course1991597226522732-s2.0-0025895712De SmetK. A. L.VordermeierH. M.IvanyiJ.A versatile system for the production of recombinant chimeric peptides19941771-224325010.1016/0022-1759(94)90162-72-s2.0-0028555866VordermeierH.-M.HarrisD. P.MorenoC.SinghM.IvanyiJ.The nature of the immunogen determines the specificity of antibodies and T cells to selected peptides of the 38 kDa mycobacterial antigen199574559566López-VidalY.de León-RosalesS. P.Castañón-ArreolaM.Rangel-FraustoM. S.Meléndez-HerradaE.Sada-DíazE.Response of IFN-γ and IgG to ESAT-6 and 38 kDa recombinant proteins and their peptides from Mycobacterium tuberculosis in tuberculosis patients and asymptomatic household contacts may indicate possible early-stage infection in the latter200435430831710.1016/j.arcmed.2004.04.0082-s2.0-4344634331ShamsH.KlucarP.WeisS. E.Characterization of a Mycobacterium tuberculosis peptide that is recognized by human CD4+ and CD8+ T cells in the context of multiple HLA alleles20041733196619772-s2.0-3242780716MustafaA. S.ShabanF. A.Al-AttiyahR.Human Th1 cell lines recognize the Mycobacterium tuberculosis ESAT-6 antigen and its peptides in association with frequently expressed HLA class II molecules200357212513410.1046/j.1365-3083.2003.01204.x2-s2.0-0037326668HarrisD. P.VordermeierH. M.FrisciaG.Genetically permissive recognition of adjacent epitopes from the 19-kDa antigen of Mycobacterium tuberculosis by human and murine T cells199315011504150502-s2.0-0027246225YoungD. B.The immune response to mycobacterial heat shock proteins1990742372442-s2.0-0025188153ShinnickT. M.Heat shock proteins as antigens of bacterial and parasitic pathogens1991167145160YoungD. B.GarbeT. R.Heat shock proteins and antigens of Mycobacterium tuberculosis1991599308630932-s2.0-0025776531OseroffC.PetersB.PasquettoV.Dissociation between epitope hierarchy and immunoprevalence in CD8 responses to vaccinia virus western reserve200818011719372022-s2.0-34250176485WinklerD. A.BurdenF. R.Nonlinear predictive modeling of MHC class II-peptide binding using Bayesian neural networks20074093653772-s2.0-44649111932HarrisD. P.HillM.VordermeierH.-M.Mutagenesis of an immunodominant Y cell epitope can affect recognition of different T and B determinants within the same antigen199734431532210.1016/S0161-5890(97)00041-22-s2.0-0030612347RothbardJ. B.GefterM. L.Interactions between immunogenic peptides and MHC proteins19919527565ReddehaseM. J.RothbardJ. B.KoszinowskiU. H.A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes198933762086516532-s2.0-0024537272HemmerB.KondoT.GranB.Minimal peptide length requirements for CD4+ T cell clones—implications for molecular mimicry and T cell survival20001233753832-s2.0-12944317215NimanH. L.HoughtenR. A.WalkerL. E.Generation of protein-reactive antibodies by short peptides is an event of high frequency: implications for the structural basis of immune recognition19838016494949532-s2.0-0040624512SchmidtW.BuschleM.ZaunerW.Cell-free tumor antigen peptide-based cancer vaccines19979473262326710.1073/pnas.94.7.32622-s2.0-0030940905GjertsenM. K.BjorheimJ.SaeterdalI.MyklebustJ.GaudernackG.Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation19977257847902-s2.0-0030749292GritzapisA. D.FridmanA.PerezS. A.HER-2/neu (657-665) represents an immunogenic epitope of HER-2/neu oncoprotein with potent antitumor properties200928116217010.1016/j.vaccine.2009.09.1042-s2.0-70649100026AskelöfP.RodmalmK.WrangsellG.Protective immunogenicity of two synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S11990874134713512-s2.0-0025138489Calvo-CalleJ. M.OliveiraG. A.WattaC. O.SoverowJ.Parra-LopezC.NardinE. H.nardie01@med.nyu.eduA linear peptide containing minimal T- and B-cell epitopes of Plasmodium falciparum circumsporozoite protein elicits protection against transgenic sporozoite challenge20067412692969392-s2.0-002362219610.1128/IAI.01151-06FarsinejadK.DaneshpazhoohM.SairafiH.BarzegarM.MortazavizadehM.Lupus vulgaris at the site of BCG vaccination: report of three cases2009345e167e16910.1111/j.1365-2230.2008.03041.x2-s2.0-66449107144EnserinkM.Public health: in the HIV era, an old TB vaccine causes new problems2007318585310592-s2.0-3624895106910.1126/science.318.5853.1059AttiaE.BCG vaccine-induced lupus vulgaris20071765475482-s2.0-36749077557HristeaA.NeacsuA.IonD. A.Streinu-CercelA.StăniceanuF.BCG-related granulomatous hepatitis200756132342-s2.0-34250835568MandavilliA.When the vaccine causes disease20071332742-s2.0-34248140232SprattA.KeyT.VivianA. J.Chronic anterior uveitis following bacille Calmette-Guérin vaccination: molecular mimicry in action?200845425225310.3928/01913913-20080701-152-s2.0-51349098502KanducD.Epitopic peptides with low similarity to the host proteome: towards biological therapies without side effects200991455310.1517/147125908026140412-s2.0-58149395884